Multivalent Vaccines Global Market Report 2024

Description

Multivalent vaccines are strategically formulated to provide protection against multiple strains or types of a single pathogen, or against several distinct pathogens, within a single administration. By incorporating antigens from various strains or diseases, these vaccines facilitate the development of immunity against multiple targets simultaneously, thereby delivering broader protection than monovalent vaccines, which focus exclusively on a single strain or pathogen.

The primary categories of multivalent vaccines include conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, toxoid vaccines, and recombinant vaccines. Conjugate vaccines enhance immune recognition and efficacy by linking a weaker antigen to a stronger one, which is particularly beneficial for combating bacterial diseases. These vaccines are applicable for a range of diseases, including influenza, pneumonia, hepatitis, meningitis, and rotavirus, and can be administered via various routes, such as oral and injectable methods. They are designed for a diverse demographic, encompassing pediatric, adult, and geriatric populations, and are distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The multivalent vaccines market research report is one of a series of new reports from The Business Research Company that provides multivalent vaccines market statistics, including multivalent vaccines industry global market size, regional shares, competitors with a multivalent vaccines market share, detailed multivalent vaccines market segments, market trends, and opportunities, and any further data you may need to thrive in the multivalent vaccines industry. These multivalent vaccines market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The multivalent vaccines market size has grown strongly in recent years. It will grow from $7.63 billion in 2023 to $8.37 billion in 2024 at a compound annual growth rate (CAGR) of 9.7%. The growth observed during the historical period can be attributed to several key factors such as heightened public awareness of vaccination, increased government support, a growing demand for pediatric multivalent vaccines, enhanced funding for vaccine research, and a rising demand for multivalent vaccines overall.

The multivalent vaccines market size is expected to see strong growth in the next few years. It will grow to $12.16 billion in 2028 at a compound annual growth rate (CAGR) of 9.8%. The projected growth during the forecast period is driven by several factors such as the rising incidence of infectious diseases, an increasing geriatric population, growing investments from both government and private sectors, heightened attention to vaccine safety and efficacy, and an expanding focus on therapeutic vaccines. Key trends expected during this period include a greater emphasis on combination vaccines, the integration of digital health technologies, advancements in mRNA technology, the development of personalized vaccines, and an increase in research activities.

The increasing prevalence of infectious diseases is projected to significantly drive the growth of the multivalent vaccines market in the near future. Infectious diseases are caused by pathogens such as bacteria, viruses, fungi, or parasites, which can be transmitted through direct contact or contaminated surfaces, air, or water, varying in severity from mild to severe. The global travel landscape facilitates the rapid spread of these diseases, allowing pathogens to easily cross borders and infect new populations. Multivalent vaccines offer broader protection against infectious diseases by targeting multiple pathogen strains in a single dose, reducing the necessity for multiple shots. This comprehensive coverage enhances herd immunity and decreases disease prevalence, thereby improving public health outcomes. For example, a report released by TravelHealthPro in April 2024 noted that the UK reported 2,004 malaria cases in 2023, an increase from the 1,369 imported cases in 2022. As a result, the rising incidences of infectious diseases are a key factor driving the growth of the multivalent vaccines market.

Leading companies in the multivalent vaccines sector are concentrating on the development of advanced pentavalent vaccines to enhance overall public health outcomes by providing wider protection in a single dose. A pentavalent vaccine is specifically designed to safeguard against five distinct pathogens or strains. This consolidation of protections simplifies immunization schedules and improves overall vaccine coverage. For instance, in December 2023, Panacea Biotec Ltd., an India-based biotechnology firm, introduced EasyFourPol, the world's first fully liquid vaccine. This innovative vaccine protects against five serious diseases, including diphtheria, tetanus, pertussis, polio, and invasive infections from Haemophilus influenzae Type B. By eliminating the need for preparation by healthcare professionals, this ready-to-use combination vaccine streamlines the vaccination process. It offers equivalent protection to single-antigen vaccines, reduces the number of clinic visits required for children, and lowers overall immunization costs. Moreover, it enhances vaccination efficiency and minimizes environmental impact by decreasing the requirement for vials, syringes, and packaging.

In February 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Icosavax Inc. for $1.1 billion. This acquisition allows AstraZeneca to strengthen its late-stage pipeline with IVX-A12, enhancing its presence in the RSV vaccine market. The deal also incorporates Icosavax's expertise in protein design and virus-like particles (VLP), providing a foundation for developing additional multivalent vaccines targeting respiratory viruses. Icosavax Inc. is a US-based biotechnology company specializing in the creation of multivalent vaccines utilizing a protein virus-like particle (VLP) platform.

Major companies operating in the multivalent vaccines market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Moderna Inc., BioNTech SE, Zydus Lifesciences Limited, CSL Seqirus, Sinovac Biotech Ltd., GC Biopharma corp., Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Indian Immunologicals Ltd., Bavarian Nordic, Panacea Biotec Ltd., WestVac Biopharma Co. Ltd., VBI Vaccines Inc.

North America was the largest region in the multivalent vaccines market in 2023. The regions covered in the multivalent vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the multivalent vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The multivalent vaccines market consists of sales of bivalent vaccines, trivalent vaccines, and polyvalent vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Multivalent Vaccines Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on multivalent vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for multivalent vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The multivalent vaccines market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Conjugate Vaccines; Inactivated And Subunit Vaccines; Live Attenuated Vaccines; Toxoid Vaccines; Recombinant Vaccines
2) By Disease: Influenza; Pneumonia; Hepatitis; Meningitis; Rotavirus
3) By Route Of Administration: Oral; Injectable
4) By Age Group: Pediatrics; Adults; Geriatrics
5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Sanofi SA; AstraZeneca plc; Abbott Laboratories
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r20294

1. Executive Summary

2. Multivalent Vaccines Market Characteristics

3. Multivalent Vaccines Market Trends And Strategies

4. Multivalent Vaccines Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Multivalent Vaccines Market Size and Growth

5.1. Global Multivalent Vaccines Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Multivalent Vaccines Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Multivalent Vaccines Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Multivalent Vaccines Market Segmentation

6.1. Global Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Conjugate Vaccines
Inactivated And Subunit Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Recombinant Vaccines
6.2. Global Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Influenza
Pneumonia
Hepatitis
Meningitis
Rotavirus
6.3. Global Multivalent Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oral
Injectable
6.4. Global Multivalent Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Pediatrics
Adults
Geriatrics
6.5. Global Multivalent Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

7. Multivalent Vaccines Market Regional And Country Analysis

7.1. Global Multivalent Vaccines Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Multivalent Vaccines Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Multivalent Vaccines Market

8.1. Asia-Pacific Multivalent Vaccines Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Multivalent Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Multivalent Vaccines Market

9.1. China Multivalent Vaccines Market Overview
9.2. China Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Multivalent Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Multivalent Vaccines Market

10.1. India Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Multivalent Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Multivalent Vaccines Market

11.1. Japan Multivalent Vaccines Market Overview
11.2. Japan Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Multivalent Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Multivalent Vaccines Market

12.1. Australia Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Multivalent Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Multivalent Vaccines Market

13.1. Indonesia Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Multivalent Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Multivalent Vaccines Market

14.1. South Korea Multivalent Vaccines Market Overview
14.2. South Korea Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Multivalent Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Multivalent Vaccines Market

15.1. Western Europe Multivalent Vaccines Market Overview
15.2. Western Europe Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Multivalent Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Multivalent Vaccines Market

16.1. UK Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Multivalent Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Multivalent Vaccines Market

17.1. Germany Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Multivalent Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Multivalent Vaccines Market

18.1. France Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Multivalent Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Multivalent Vaccines Market

19.1. Italy Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Multivalent Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Multivalent Vaccines Market

20.1. Spain Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Multivalent Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Multivalent Vaccines Market

21.1. Eastern Europe Multivalent Vaccines Market Overview
21.2. Eastern Europe Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Multivalent Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Multivalent Vaccines Market

22.1. Russia Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Multivalent Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Multivalent Vaccines Market

23.1. North America Multivalent Vaccines Market Overview
23.2. North America Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Multivalent Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Multivalent Vaccines Market

24.1. USA Multivalent Vaccines Market Overview
24.2. USA Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Multivalent Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Multivalent Vaccines Market

25.1. Canada Multivalent Vaccines Market Overview
25.2. Canada Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Multivalent Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Multivalent Vaccines Market

26.1. South America Multivalent Vaccines Market Overview
26.2. South America Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Multivalent Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Multivalent Vaccines Market

27.1. Brazil Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Multivalent Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Multivalent Vaccines Market

28.1. Middle East Multivalent Vaccines Market Overview
28.2. Middle East Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Multivalent Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Multivalent Vaccines Market

29.1. Africa Multivalent Vaccines Market Overview
29.2. Africa Multivalent Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Multivalent Vaccines Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Multivalent Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Multivalent Vaccines Market Competitive Landscape And Company Profiles

30.1. Multivalent Vaccines Market Competitive Landscape
30.2. Multivalent Vaccines Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Merck & Co. Inc.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Sanofi SA
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. AstraZeneca plc
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Abbott Laboratories
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Multivalent Vaccines Market Other Major And Innovative Companies

31.1. Novartis AG
31.2. GlaxoSmithKline plc
31.3. Boehringer Ingelheim International GmbH
31.4. Moderna Inc.
31.5. BioNTech SE
31.6. Zydus Lifesciences Limited
31.7. CSL Seqirus
31.8. Sinovac Biotech Ltd.
31.9. GC Biopharma corp.
31.10. Emergent BioSolutions Inc.
31.11. Serum Institute of India Pvt. Ltd.
31.12. Indian Immunologicals Ltd.
31.13. Bavarian Nordic
31.14. Panacea Biotec Ltd.
31.15. WestVac Biopharma Co. Ltd.

32. Global Multivalent Vaccines Market Competitive Benchmarking

33. Global Multivalent Vaccines Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Multivalent Vaccines Market

35. Multivalent Vaccines Market Future Outlook and Potential Analysis

35.1 Multivalent Vaccines Market In 2028 - Countries Offering Most New Opportunities
35.2 Multivalent Vaccines Market In 2028 - Segments Offering Most New Opportunities
35.3 Multivalent Vaccines Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer